Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Skkynet Cloud Systems, Inc. (SKKY) Secure Cloud Service™ to Be Featured at Smart Energy Show in Japan

Today before the opening bell, Skkynet, a global leader in real-time cloud information systems, reported its Secure Cloud Service™ will be featured at the upcoming Smart Energy Show later this month in Japan. There, the Thundercloud™ Alliance will be presenting the service to 10,000-plus embedded system designers and builders. The presentation will include interactive displays to showcase the service’s functionality, real-time performance, and ease-of-use.

Smart Energy Japan is a two-day event in which the public is introduced to different equipment and systems available for controlling energy consumption for consumer, commercial, and industrial user applications. This year’s event will be taking place at the Grand Front Osaka in Osaka, Japan on Tuesday and Wednesday, July 29 and 30, 2014.

The Thundercloud™ Alliance is a group formed in December 2013 by between TOA Musendenki, Nissin Systems, BellChild, NiC, KOBATA Gauge, and Skkynet. It was founded to develop a turnkey, real-time sensor-to-cloud service for the industrial machine-to-machine market.

“This is an excellent opportunity for those at the forefront of embedded systems development in the smart energy sector to see and interact with a fully functional, end-to-end, cloud-based system firsthand,” said Paul Thomas, President of Skkynet. “We are looking forward to some engaging questions and serious conversations.”

The Secure Cloud Service™ is expected to be released on Wednesday, August 13, 2014. It will also be featured at the upcoming M2M Conference on August 12-14 in Las Vegas, Nevada.

For more information, please visit: www.skkynet.com

Let us hear your thoughts:

Posted in Small Cap News | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Announces New Agreement with Largest Shareholder

In an 8-K filed with the SEC today, VistaGen Therapeutics announced that Platinum Long Term Growth VII, LLC, the company’s largest investor, has entered into an Amended and Restated Note Conversion Agreement and Warrant Amendment.

According the SEC filing, Platinum has agreed to convert all senior secured convertible promissory notes currently held into unregistered equity securities upon the consummation on or before August 31, 2014, of either a private equity financing resulting in aggregate gross proceeds of at least $36.0 million, or a registered equity financing resulting in gross proceeds of $10.0 million or more. The deal would significantly improve VistaGen’s balance sheet.

Additionally, pursuant to the terms and conditions of the amendment and consummation of a qualified financing on or before August 31, 2014, the exercise price of all warrants issued by VistaGen to Platinum in connection with the notes, and warrants that still may be issued pursuant to the note exchange and purchase agreement dated October 11, 2012, if any, will be fixed at $0.50 per share or the purchase price of common stock sold in the qualified financing, whichever is lower. Finally, the anti-dilutive provisions contained in the warrants, other than typical adjustments for stock splits, combinations and dividends, will be terminated.

Platinum also agreed to terminate the amended and restated security agreement, intellectual property security and stock pledge agreement and negative covenant agreement, each dated October 11, 2012, related to the Notes, and release all of its security interests in the assets of VistaGen and its subsidiaries in connection with the company’s completion of a Qualified Financing and conversion of the Notes.

To read the whole filing, visit www.dtg.fm/vsta-8k-7-22-14

For more information on VistaGen, visit www.vistagen.com

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

What You Need to Know about Canada’s New Anti-Spamming Legislation

In an effort to beef-up the Canadian online marketplace, Canada recently passed new anti-spam legislation (CASL). Changes in Canadian e-communication laws were unfurled July 1, 2014, and whether you’re based in Canada, the United States or Dubai, if you haven’t noticed the change just yet, you may soon feel the ripples in the way you receive and share email communication with recipients up north.

In short, the CASL runs counter to the traditional opt-out or unsubscribe models to stop receiving unwanted email, and instead includes a strict opt-in model for B2B email messaging whereby recipients must proactively agree to receive email from businesses.

Per the legislation, if you are sending a commercial electronic message (CEM) to a Canadian recipient, you need to comply with three requirements: obtain oral or written consent; provide identification information; and provide an unsubscribe mechanism.

CEMs are emails inclusive of the promotion of a product or service that encourages the recipient to purchase the item or services. This includes the promotion of people, public image, goods, land or even a business, investment or gaming opportunity. There is an exemption for persons sending CEMs to other persons within their organization, as well as for communication between two organizations that have a business relationship.

Think twice before you consider toeing the line with CASL. Committing a violation under CASL can carry a hefty fine – up to $1 million for an individual and up to $10 million for a business.

For more information visit www.crtc.gc.ca

Let us hear your thoughts below:

Posted in Small Cap News | Leave a comment

Continental Stock Transfer & Trust Company Answers Your Questions

Continental Stock Transfer & Trust Company’s commitment to accessibility and service, focused on small to medium emerging and growth companies, has always been a cornerstone of their stated mission, differentiating them in the marketplace. They go out of their way to make it easy for clients and shareholders to get answers, and they know the most common questions, some of which are shown below.

• What are the best ways for shareholders to contact Continental Stock Transfer & Trust Company?

• How should a shareholder change their mailing address?

• How can you replace a lost stock certificate?

• How can shares be sold?

• How can you tell if an old security still has value?

• How can you replace a dividend check?

• Why was tax withheld from a dividend payment?

• How to obtain a copy or a corrected Form 1099?

• How to exchange certificates for DRS shares?

• What’s the best way to mail shares for transfer to Continental?

• How to transfer (change ownership) of shares?

• What are the most common types of security registrations?

• How are shares transferred out of a decedent’s name?

• How is a deceased joint tenant removed as a registered holder?

• What is a beneficial shareholder, versus registered shareholder?

• What is a guarantor?

• What is a Medallion Guarantee?

For the answers to these and other questions, visit www.ContinentalStock.com/faqs

Let us hear your thoughts below:

Posted in Small Cap News | Leave a comment

Windstream Technologies (WSTI) Plays Key Role in World’s Largest Hybrid Renewable Energy Project

Windstream Technologies is playing a pivotal role in the world’s largest hybrid renewable energy project. Commissioned on the roof of law firm Myers, Fletcher and Gordon (MFG) in Kingston, Jamaica, and being referred to as a landmark urban installation, the project consists of 50 WindStream SolarMill® units used to capture available wind and solar resources.

The installation is expected to generate over 106,000 kWh of renewable energy each year, (25kW of wind and 55kW of solar) with a return on investment of less than four years. Over the course of an approximate 25-year life span, the energy cost savings are expected to exceed $2 million. WindStream was awarded the project due to its ability to maximize energy production and return on investment – all in an area consisting of limited roof space.

“We have been at the forefront of the Jamaican legal landscape for 70 years and we are pleased to be continuing that trend by leading inJamaican sustainability and renewable energy,” said Donovan Cunningham, COO of Myers Fletcher & Gordon. “This was a bold undertaking and we expect to reap rich rewards through our partnership with WindStream.”

The MFG SolarMill installation is a component of an overall effort by Jamaica Public Service (JPS) to provide greater access to renewable energy solutions in a country where the cost of energy is over three times the US average. JPS and WindStream also worked with Eaton Houghton of Caribbean ESCO as the Caribbean’s lead energy efficiency auditor for the project.

“We are proud to be working with JPS, which is distributing our products within Jamaica and throughout the Caribbean,” said Travis Campbell, COO of WindStream Technologies. “This SolarMill installation is an excellent model for other businesses to follow. If you are interested in energy efficiency and saving money, SolarMills are a simple, cost-effective solution.”

WindStream Technologies, founded in 2008, is a public company headquartered in North Vernon, Indiana. WSTI’s mission is to create low-cost hybrid, renewable energy solutions for on and off-grid, urban and suburban environments. Made in the USA, its patented SolarMill® technology is a distributed energy solution that produces constant renewable energy for customers. The company’s products are sold around the world.

For more information on the company, visit www.windstream-inc.com

Posted in Small Cap News | Leave a comment

Millions in Grant Funding Provide Foundation of Opportunity for VistaGen Therapeutics, Inc. (VSTA)

The National Institute of Health aims to supports biomedical science and behavioral research through the pursuit of knowledge of the biology and behavior of living systems and to then apply that knowledge to “extend healthy life and reduce the burdens of illness and disability.” NIH’s own role in this mission includes the provision of funding grants and/or cooperative agreements. To ensure that funds are allocated to organizations aligned with this goal, NIH first determines whether or not the applying company’s project will yield a “sustained, powerful influence on the research field(s) involved.”

Obtaining a grant is much more than a simple petition and business plan. In order for a company to receive a grant from NIH, an applying company’s project must undergo peer review and demonstrate, in addition to other considerations, the following five criteria:

• Significance – address an important problem or critical barrier to progress in the field; Investigators – doctors, collaborators and other researchers must be well-suited, experienced and trained for the project;
• Innovation – the application must challenge and seek to shift current research or clinical practice by utilizing novel concepts, approaches, instrumentation or intervention;
• Approach – appropriately strategized to accomplish the specific aim of the project; and
• Environment – will scientific environment in which the work will be conducted contribute to the probability of success?

The rewards of meeting these criteria are often invaluable. Case in point: VistaGen, Inc., a San Francisco-based stem cell company focused on drug rescue and regenerative medicine backed by a team of stem cell research and development teams and collaborators that for 15 years have focused on controlling the differentiation of pluripotent stem cells to produce multiple types of mature, functional, adult human cells for drug rescue applications.

Since its inception in 1998, the company has received a total of $8.8 million in grant funding from the NIH for phase 1 clinical development of its AV-101 lead small molecule drug candidate.

This funding enabled the company to complete phase 1 development of AV-101, an orally available small molecule prodrug candidate designed to address needs in the multi-billion dollar neurological disease disorders market, such as neuropathic pain, epilepsy and depression. VistaGen has submitted an AV-101 IND application with the U.S. FDA to cover clinical development for neuropathic pain, though the company believes that completed phase 1 AV-101 safety studies will also support development of AV-101 for multiple indications, including epilepsy and depression.

VistaGen’s plan, contingent upon completion of this offering, is to pursue potential opportunities for further development and commercialization of AV-101 on a stand-alone or corporate partnership basis. If successful, the company says it intends to use the net proceeds from such an arrangement to expand its drug rescue and regenerative medicine programs, which are based on its stem cell technology platform, Human Clinical Trials in a Test Tube™.

Receiving NIH funding marked a pivotal moment in VistaGen’s history, providing the company with a monetary avenue to pursue its broader mission to commercialize therapeutically and commercially promising regenerative medicine programs.

For more information, visit www.VistaGen.com

Let us hear your thoughts:

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

TraderPower – Empowering Investors to Discover Exceptional Opportunities

TraderPower was established to empower investors with all the resources they need to make profitable trading decisions. Using the vast resources on the TraderPower website, the investment community can discover undervalued small-cap companies, learn how to properly analyze investment opportunities, and utilize free research tools for in-depth evaluation.

TraderPower’s #1 focus is on connecting investors with undervalued small-cap companies that are trading far below their true worth. With an estimated 15,000 publicly traded companies, it’s no surprise that these stocks exist. Of course once these neglected equities begin to get noticed, the climb to their fair valuation can be exceptionally profitable in a very short time.

Want to learn more? Visit www.TraderPower.com and discover your next profitable investment

Let us hear your thoughts below:

Posted in Small Cap News | Leave a comment

Stellar Biotechnologies, Inc. (SBOTF) Reports Q3 2014 Financial Results and Corporate Update

Stellar Biotechnologies, a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today reported its financial results for the third quarter and nine months ended May 31, 2014. It also provided a few operational highlights from that time frame as well.

Financial Results:

Cash Position: Cash and cash equivalents as of May 31, 2014 were $14.8 million, compared to $ 7.9 million at year-end August 31, 2013. The Company believes current cash will be sufficient to meet estimated working capital requirements and fund planned program development through 2015. During the nine months ended May 31, 2014, the Company received $7 million gross proceeds under private placements (with $5 million of the September 2013 private placement subscribed and received prior to August 31, 2013) and $4.2 million gross proceeds from the exercise of warrants and options.

Shareholder Statistics: As of May 31, 2014, Stellar had shareholders equity of $11.1 million and approximately 78 million shares outstanding.

Revenues: Revenues were $102,581 in the third quarter and $252,848 for the nine months ended May 31, 2014 compared to $73,214 and $250,422 in the comparable periods in 2013. Stellar completed the NSF Phase IIB grant during the first quarter of 2014 and generated additional contract and commercial sales revenue during the second and third quarter.

R&D Expenses: Research and development expenses were $462,129 in the third quarter of 2014 and $1.37 million in the nine months ended May 31, 2014, compared to $178,202 and $684,662 in the comparable periods in 2013. The increase in R&D expense was largely due to an increase in method development activities for vaccine manufacturing during the period related to the C. diff active immunotherapy research program.

Other Operating Expenses: Other operating expenses totaled $864,485 in the third quarter of 2014 and $2.98 million in the nine months ended May 31, 2014, compared to $582,152 and $1.74 million in the comparable periods in 2013. The increase was primarily attributable to a higher level of activity, addition of key personnel, vesting and timing of stock options, and discontinuation of the temporary voluntary salary reduction that were initiated in the prior comparison period.

Net Income (Loss): Net income was $1.81 million for the third quarter of 2014 and a net loss of $3.8 million for the nine months ended May 31, 2014, compared to net loss of $1.17 million and $5.58 million for the comparable periods in 2013. The decrease of $2.98 million in net loss for the third quarter of 2014, and cumulative decrease of $1.78 million net loss for the nine months ended May 31, 2014 were substantially affected by fluctuations in noncash change in fair value of warrant liability. During the three months ended May 31, 2014, there was a gain on fair value of warrant liability of $3.02 million (2013 – loss of $353,119) for a net fluctuation of $3.38 million additional gain than the prior period. The gains and losses in these periods are a reflection of the Company’s share price fluctuations with increases in share prices causing greater warrant liability and a loss on fair value of warrant liability, while decreases in share prices cause a gain on fair value of warrant liability. Changes in fair value of warrant liability have no impact on cash flow. If the warrants are exercised, the warrant liability is reclassified to share capital. If the warrants expire, the decrease in warrant liability offsets the changes in fair value.

Operational Updates:

Collaborations and KLH Supply Agreements: Stellar KLH(TM) is currently used by the Company’s biopharma partners as the carrier in certain new immunotherapies in clinical development for cancer, autoimmune disease, and inflammatory disease. Those programs continued to progress in 2014 and Stellar met all contract requirements related to supply and/or development of KLH protein for those product candidates. In addition, Stellar continues to strengthen its collaboration expansion with biopharma companies as their immunotherapy programs advance in the clinic to later stages of development and potential regulatory submissions. These strategic collaborations represent multiple commercial pathways for Stellar including future growth of core business sales and close involvement in the development of new KLH-based immunotherapies.

C. diff Active Immunotherapy Program: During the first half of 2014, Stellar successfully advanced its C. diff active immunotherapy program in key preclinical areas including early process development and the scale-up and transfer of essential manufacturing methods to a contract manufacturing organization (CMO). The goal of this stage of product development is to establish scalable processes necessary to support GMP production of a PS-KLH conjugate vaccine candidate. In the second half of 2014, the Company will focus on completing certain IND-enabling milestones such as identification of appropriate PS-KLH formulation, demonstration of dose ranging and safety, intermediary scale-up and manufacturing of test material in preparation for clinical production.

“This has been an important strategic year for Stellar and we are pleased to report positive momentum in key facets of our KLH business,” said Frank Oakes, President and CEO of Stellar Biotechnologies. “Our corporate collaborations, where Stellar KLH is used as the critical carrier molecule in new therapeutic vaccines, are strong and poised for clinical advancement. And we are on track in the preclinical development of our own C. diff immunotherapy program. We are confident that these initiatives will enhance valuation for our shareholders as well as expand Stellar’s long-term commercial potential.”

For more information about Stellar Biotechnologies, please visit: www.stellarbiotech.com

Let us hear your thoughts:

Posted in Small Cap News | Leave a comment

Breitling Energy Corp. (BECC) Helps ‘Tee Up’ America’s Solution to Dependence on Imported Oil

Is fracking technology, the hydraulic process that enables the extraction of domestic oil and natural gas from shale-rock deposits, the magic bullet? The one that will finally slay the Middle East’s oilfield mega-gorilla who’s been holding the U.S. and much of the rest of the energy-thirsty western world hostage since the 1970s?

To many oil industry engineers, economists, financial analysts and executives, like Breitling Energy Corporation’s CEO, president and chairman Chris Faulkner, the question isn’t really about whether the technology will achieve the desired end result, but when it will do so. And the answer most experts tracking the industry believe is “right about now.”

According to the International Energy Agency, the United States — thanks in large part to advances in fracking efficiency pioneered by Breitling and others — will, by the end of 2014, surpass Russia and Saudi Arabia to become the world’s top oil producer for the first time in almost 50 years.

Though some oil company veterans have been a bit slow to realize the major implications of North Dakota’s Bakken Field, Montana’s Three Forks reserves, and other oil-and-gas-bearing shale deposits, Breitling’s Faulkner is one Texas oilman who not only saw the handwriting on the wall early on, but helped put it there.

Faulkner, author of the recently published book The Fracking Truth, executive producer of “Breaking Free,” a film about the shale-oil revolution, and winner of numerous “industry leader of the year,” “oil executive of the year,” and “best North American [energy company] operator of the year” awards, notes that “fracking has teed up America to solve this problem (of dependence on foreign sources to fuel its economy) with less risk and at greater gain than any other nation on earth.”

Headquartered in Dallas, Texas, Breitling has planted its drilling roots deeply in both old school and new age methods of finding oil and natural-gas deposits and wrestling them from their ancient hiding places. Their avowedly “lower-risk acquisition, exploration and development” operations are focused on preliminary and secondary oil and natural gas recovery in both traditional U.S. “oil play” areas and “shale play” (also known as “unconventional liquid play” to industry insiders) sites such as the Marcellus range in the Appalachians, Eagle Ford, Texas, Three Forks in Montana, and, of course, the Bakken fields in North Dakota.

By using state-of-the-art technologies such as 3D seismic modeling and CO2 tertiary-recovery technology, Breitling has frequently been able to reduce costs and improve yields to the point where even abandoned drilling fields previously believed unworkable are now yielding significant bottom-line returns.

“Our operating areas are characterized by long-lived natural gas and oil reserves and established production capabilities, with abundant growth opportunities. In each of the company’s operating areas, our deep backlog of drilling locations enables us to establish substantial economies of scale in drilling and production operations for more effective drilling and reservoir management practices,” Faulkner says.

Winner of the IAIR 2014 “Best Company Award for Leadership in Oil & Gas Extraction in the USA” and the 2013 “Aggreko Award for Excellence in Environmental Stewardship” in the Gulf Coast Region, Breitling’s culture is based on the concept that energy production, economic growth and development, and a clean and healthy environment are mutually inclusive rather than mutually exclusive.

“Being honored by the IAIR, whose panel of judges includes scientists and experts in law and finance from more than 120 nations, highlights an incredible decade of achievements and successes since Breitling’s founding in 2004,” states Faulkner.

“Between the release of the documentary ‘Gasland’ and the Deepwater Horizon disaster, I was stunned at how poorly the industry responded,” Faulkner said in a recent issue of “Energy Executive” magazine. “We still have a long way to go in trying to tell the full story. What I’ve learned through experience is that we have to do a much better job of getting our story out there, with full transparency and a willingness to face the tough questions.”

Among other core beliefs rooted in transparency toward shareholders, the public, and regulators, Faulkner believes the best way to handle tough questions is to meet them with responsive solutions. Which is one reason why he founded the Breitling Oil and Gas EnviroFrac™ research program in early 2010.

EnviroFrac™ scientists are charged with evaluating the environmental impact of additives typically used in hydraulic fracking operations and developing greener alternatives for those additives which pose either current or potential ecological hazards.

“EnviroFrac™ is a decisive move toward a greener fluid system,” Faulkner notes. “By reviewing all of the ingredients used in each frac, the program identifies chemicals that can be removed and tests alternatives for remaining additives. We are very proud that we have, to date, eliminated 25 percent of the additives that used to be key components in our shale operations. Our eventual goal is to replace any that pose even a slight threat to the people who work at or live adjacent to our project sites.”

For more information, visit www.breitlingenergy.com

Posted in Small Cap News | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) at Forefront of Stem Cell Technology for Drug Rescue, Regenerative Medicine, Small Molecule Drugs

VistaGen Therapeutics stands at the forefront today of the rapidly developing world of stem cell technology, with a tight portfolio of IP that cuts hard and fast across multiple, critical applications in the areas of drug rescue and regenerative medicine. The company’s Human Clinical Trials in a Test Tube™ platform fuses together proprietary technologies for controlled development/differentiation of human pluripotent (having the potential to differentiate into almost any cell) stem cells into many types of mature, functional adult cells and the utilization thereof.

This incredible capacity to produce large quantities of functional adult cells has thus far led to two 3D “micro-organ” bioassay system applications for drug rescue, CardioSafe 3D™ and LiverSafe 3D™. Using stem cell-derived, functional heart and liver cells (respectively) to create mock-up 3D cell networks and tissue structures, which accurately model the actual organs in the body, presents the multibillion dollar pharma development space with a safer small molecule Drug Rescue Variant™ solution pathway. This salvage opportunity technology is able to help drug developers recoup the massive capital outlays associated with creating once-promising new drug candidates that got dropped due to bad drug interactions and/or toxicity concerns, in essence offering drug developers a way to hit the reset switch and come away with a safer, more effective product instead of lost capital. Moreover, CardioSafe 3D and LiverSafe 3D offer pharma developers a drug metabolism and toxicity screening solution that ably surmounts one of the major causes of the high failure rates among otherwise promising drug candidates, the persistent limitations of preclinical drug testing.

VistaGen is also developing a novel, orally available small molecule prodrug candidate known as AV-101, which has shown solid results in Phase 1 clinical development for neuropathic pain in the U.S., under an active Investigational New Drug application with the FDA. With apparent traction in depression and epilepsy, as well as potentially in other neurological conditions, including Parkinson’s, AV-101 is of particular interest in that it acts as a synthetic analog for a naturally-occurring regulatory compound in the central nervous system, kynurenic acid (AV-101 converts into the analog, 7-chlorokynurenic acid, inside the brain). High oral bioavailability, excellent blood-brain barrier transport dynamics and preferential conversion to synthetic kynurenic acid at sites of neural damage, all reinforce the $8.8M in funding VSTA has received from the NIH for AV-101′s development.

Advancements in the broader stem cell space, like the recent announcement that Japanese researchers at the RIKEN Center for Life Science Technologies have identified how CCL2 (a chemokine that plays a role in immune response) functions as a pluripotency enhancer in human induced pluripotent stem cells, makes VSTA’s portfolio start to look more and more interesting. The potential for modeling drug interactions in vitro with high-fidelity in vivo results guidance (long before substantial development costs start to add up), as well as the potential to salvage otherwise deprecated, yet promising drug candidates, combined with an eventual ability to re-grow various tissues and break through to new horizons in regenerative medicine, makes VSTA an exciting company for its size and market cap. Inducing the body to take up cultured stem cells and re-grow blood, bones, cartilage and other tissues, even heart, liver and pancreatic tissue, is serious blue sky potential that may even dwarf the value of chemical variant salvaging on drug candidates for pharmaceutical and biotech customers.

With recent patent expansions in both the U.S. and Canada this year for their stem cell technology platform, VistaGen is feeling supremely confident about the company’s performance. CEO of VSTA, Shawn K. Singh, JD, even noted how the Canadian patent allowance in particular expands the company’s core IP in a key target market the company has been after for years now. This particular patent, under exclusive license from the Icahn School of Medicine, Mount Sinai, New York, covers pluripotent stem cell culture systems which produce endoderm lineage cells, including liver, lung, pancreas, parathyroid, and thyroid cells. The equivalent U.S. patent expansion covers three patents under similar license and roundly reinforces the company’s already strong LiverSafe 3D position, while also opening up collaboration potential in the area of liver biology and drug metabolism assay, as well as regenerative therapy for diabetes using pancreatic beta-islet cells.

The recent (July 2) announcement that University at Buffalo researchers have identified the “master switch” which triggers myelination in the brain, a process where fatty layering (a sign of healthy central nervous system functionality) accumulates on the neuronal axon (or main shaft), allowing the brain cell to transmit data quickly and reliably (enabling more complex brain activity to take place), should give investors some idea of where this sector is heading. The identification of this “master switch,” a transcription factor in human brain cells known as SOX10, puts multiple sclerosis for instance directly in the crosshairs for development of an efficient treatment. An MS treatment based on transplantation of myelin-generating progenitor cells that doesn’t take a year or more, says it all about the potential of the stem cell space really. In this particular case the potential exists for a small molecule drug candidate that could switch on SOX10 as well.

The immense potential of stem cell technology for fundamentally transforming several areas of medicine is fully inherent in companies like VistaGen Therapeutics, whether we are talking small molecule drug development or regenerative stem cell therapies and organ modeling.

More data on VistaGen Therapeutics is available at: www.VistaGen.com

Let us hear your thoughts below:

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment